Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2019-02-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
国信证券股份有限公司关于公司2018年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an opinion from Guosen Securities Co., Ltd. regarding the 2018 internal control self-evaluation report of Te Yi Pharmaceutical Group Co., Ltd. It references regulatory guidelines related to securities issuance and listing, internal control standards, and details the scope, structure, and evaluation criteria of internal controls. The document contains detailed analysis and conclusions about the internal control effectiveness and defect identification for the fiscal year 2018. It is a standalone audit-related opinion on internal controls rather than a full annual report or financial statement. The document length is 7130 characters, which is substantive and contains detailed content, not just an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR), which includes audit reports and internal control evaluations separate from full annual reports. FY 2018
2019-02-27 Chinese
独立董事关于相关事项的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent directors' opinion on various company matters for the year 2018, including related party fund occupation, external guarantees, profit distribution proposal, use of raised funds, internal control evaluation, audit firm reappointment, and bank credit guarantees. It references compliance with regulatory guidelines and company rules, and provides independent opinions on these issues. The document is dated February 27, 2019, and is signed by independent directors. It does not contain full financial statements or detailed financial performance data, but rather is a formal opinion report on governance and compliance matters related to the annual period. This type of document aligns with an Audit Report / Information (AR) category, as it includes audit-related opinions, internal control evaluation, and compliance with regulatory requirements, but is not a full Annual Report (10-K) or Interim Report (IR). The document length is 2517 characters, which is consistent with a standalone audit or compliance opinion report rather than a full annual report. Therefore, the best classification is AR with high confidence. FY 2018
2019-02-27 Chinese
关于第四届监事会第三次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolutions passed at the third meeting of the fourth Supervisory Board of 特一药业集团股份有限公司. It includes approval of the 2018 Supervisory Board Work Report, the 2018 Financial Final Accounts Report, the 2018 Profit Distribution Plan, the 2018 Annual Report, the 2018 Internal Control Self-Evaluation Report, a special report on the annual deposit and actual use of raised funds, the reappointment of the financial audit institution, the 2019 R&D budget, and a proposal for applying for a comprehensive credit line and guarantees. The document is a formal announcement of meeting resolutions and does not contain the full annual report or detailed financial statements itself. It also states that these matters will be submitted to the shareholders' meeting for approval. The document length is short (1698 characters), and it serves as a meeting resolution announcement rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement of supervisory board meeting resolutions and related approvals.
2019-02-27 Chinese
关于公司控股股东及其他关联方资金占用情况汇总表的专项审核报告
Regulatory Filings
2019-02-27 Chinese
2018年度独立董事述职报告（尹荔松）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2018 by an independent director of the company. It details the director's attendance at board meetings, opinions given, committee work, investigations, and supervision activities during the year. The content focuses on governance, oversight, and the director's duties rather than financial results or audit opinions. It is not a full annual report, audit report, or earnings release. It is a detailed report by a board member about their activities and governance role, which fits best under Board/Management Information (MANG). The document length is under 5,000 characters and is a report itself, not an announcement or certification, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2019-02-27 Chinese
2018年度独立董事述职报告（杨小龙）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2018 by an independent director of the company. It details the director's attendance at board meetings and shareholder meetings, opinions expressed on various company matters, participation in board committees, supervision of company governance and internal controls, and other duties performed during the year. The document is a narrative report on the independent director's activities and oversight role rather than a financial report or regulatory filing. It does not contain financial statements or audit opinions, nor is it an announcement of voting results or management changes. It is a specialized report related to board/management oversight and governance activities. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 3004 characters, which is relatively short but contains substantive content about board activities, not just an announcement or certification, so it is not RNS or RPA.
2019-02-27 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.